Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. - Wikidata - awgldk - TriplyDB

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q36931971

about

Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder Defining the role of the Bcl-2 family proteins in Huntington's disease Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases?Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.Exercise is not beneficial and may accelerate symptom onset in a mouse model of Huntington's disease Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer's disease Iron accumulates in Huntington's disease neurons: protection by deferoxamine Localized CT-guided irradiation inhibits neurogenesis in specific regions of the adult mouse brain.Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.Neuroprotective potential of escitalopram against behavioral, mitochondrial and oxidative dysfunction induced by 3-nitropropionic acid.Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.Evaluation of a cone beam computed tomography geometry for image guided small animal irradiation Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model Huntingtons Disease Mice Infected with Toxoplasma gondii Demonstrate Early Kynurenine Pathway Activation, Altered CD8+ T-Cell Responses, and Premature Mortality.Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin.Extensive changes in DNA methylation are associated with expression of mutant huntingtin.Targeting sirtuin-1 in Huntington's disease: rationale and current status.Targeting H3K4 trimethylation in Huntington disease Patterns of serotonergic antidepressant usage in prodromal Huntington disease A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.From neurotransmitters to neurotrophic factors to neurogenesis.Functional interrogation of adult hypothalamic neurogenesis with focal radiological inhibition.Preventing late-life depression: a clinical update.Molecular mechanisms and potential therapeutical targets in Huntington's disease.A review: treatment of Alzheimer's disease discovered in repurposed agents.Antidepressants for neuro-regeneration: from depression to Alzheimer's disease.Neuroprotective effects of psychotropic drugs in Huntington's disease Potential therapeutic targets in polyglutamine-mediated diseases.From pathways to targets: understanding the mechanisms behind polyglutamine disease.Sertraline increases the survival of retinoic acid induced neuronal cells but not glial cells from human mesenchymal stem cells.

P2860

Q21131050-9C9997B1-120A-49AE-A8F0-BF3FBC8E87C6 Q24626017-4CD54E4D-F2C9-4AAA-AF42-285753047C93 Q26822846-0219D912-B40D-4AF1-A14F-50B6A75AF69E Q27005950-A0C63018-D37E-4868-85EF-53A608A89B63 Q27012489-F4689F02-7347-424D-93CB-1E863DA1C537 Q27314860-DE0F5F90-12E5-4908-B1A3-26747B6EED25 Q28594357-6B7F71F1-0327-417C-8F96-09BA8564F0D2 Q33713689-6C513ECB-67D2-42C2-BF4D-EF5E3321ECCB Q33769984-04B23736-7966-45FA-8D78-2B765F7E1DA1 Q33869789-2C216157-ABFB-4556-B735-21597AA2E432 Q34330172-0A7E5277-9A01-4EA6-ACBA-26D8A092F732 Q34505628-8FECC084-5C0C-4146-9CA5-D6FE49401541 Q34700226-45D35F2E-9094-4E31-A3C0-A370CE7E83D5 Q35023030-ECA4062E-9037-40E2-BC93-4F5DA925B7CB Q35125801-9FCE0EA9-BF1A-4DCF-8445-0005B0A46A11 Q35158376-18AF77A3-5A51-471E-850D-4D9FDD4F9074 Q35253106-6911C664-73C3-4A5B-B5D2-B421BE39C7BD Q35356604-F5B1BEC3-09BA-43B4-AAF2-7D9E55416A28 Q35540810-DFEB5738-12E0-4040-A487-2E848562C76C Q35874667-87D3F503-5314-4463-B964-943445583E7C Q35920027-A9BFABD4-21E9-402A-B254-4E27DD6048A0 Q36024880-24EAA9AC-15FE-412C-AF2C-45A5DB7AF369 Q36025447-A9E9F928-D6B9-4B9B-8F04-42C2E9606C3F Q36128464-657C1AF4-13DD-4F50-9C93-843FD044EB18 Q36319566-A736563A-4DBD-4A20-B24B-663DF02363C8 Q36598186-B1EE84C6-3943-429D-8FDB-409E71C52D43 Q36863901-35D08B8B-6948-4DF1-ACA2-102BBF171321 Q37088721-B27D3133-D4CB-4453-9E32-B1E777BC0FD9 Q37148863-4BB47284-B96F-4AE2-A6B8-D404C7CD4BE9 Q37345118-475CE546-E4ED-4BCE-AAAC-284B71EC0F20 Q37393550-A2C342B1-351F-4443-853D-68C49C6FCBBE Q37709176-B3B173DC-F382-4E33-9F99-CCFA363D3E2D Q37769293-EB016591-7398-48C2-ADC2-7522414FCA0E Q37776087-FE6ABFE1-D5D2-48DB-A7F5-ED8B1AEBBEDE Q38073138-9F1392B0-B89C-4467-AAE7-E4F44B2DC948 Q38152966-D7B403C1-E3B2-4C43-8DB2-D56F0E360FDB Q38163877-EFF41CC2-D420-4FCA-9B21-C9EFEAC12E73 Q38246221-22F77C87-3B60-4B61-B05A-D5A341E256AC Q38259591-AA57BAA1-A806-40FB-A424-3F4B13DD5E0C Q39213199-EC7C8192-5DAE-4CF1-9DF1-3123336FB54A

P2860

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q36931971

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Sertraline slows disease progr ...... model of Huntington's disease.

@en

type

label

Sertraline slows disease progr ...... model of Huntington's disease.

@en

prefLabel

Sertraline slows disease progr ...... model of Huntington's disease.

@en

P1433

Q36931971-20E6E240-29C0-4D1B-A791-02EE935FBDA8

P1476

Q36931971-6F3A90CD-7A90-4F9B-9BBB-A0D5E37B5AC8

P2093

Q36931971-34A1696D-AE46-49E5-B19B-4E4579F41E62

Q36931971-83639FAD-2179-498C-A972-3E47E478D140

Q36931971-95DC5CFB-7A41-4A02-ACDF-686EC4E61966

Q36931971-97D9BE95-65E9-410B-B8F4-1EAC4502B406

Q36931971-A0E8A747-1CAC-4AD2-8408-7F2BE134355F

Q36931971-A478907B-9422-40B0-8AC5-FDB1BC446B1D

Q36931971-C6AFBE2E-0B57-42A5-921E-46ED2D613ADC

Q36931971-E0980C81-D63D-4B26-81C5-3D8B9AAB9010

Q36931971-F15DD71F-433E-4AF0-A7C3-D65D03FF0585

P2860

Q36931971-00EED147-4067-4683-B285-1AB9A55D51E1

Q36931971-0CE9F76F-D258-4145-B5C6-D1EA32A8E571

Q36931971-11021D1C-755A-4043-AB1C-A2B4B0F4EA01

Q36931971-1B73FA38-6768-4FD7-8F74-54A0305E1938

Q36931971-1C377573-A48A-4D4E-AFF0-E1BEE9D15BA5

Q36931971-1CC53B39-C10F-4F82-BD57-2B7177DEC1E8

Q36931971-1F5C2A4E-0A93-4D98-B688-6F05B008086F

Q36931971-2687FDD5-D7A9-45B3-B061-DD99D4A1A281

Q36931971-27137D66-771F-4AA0-9A25-1D47EC348941

Q36931971-28B8C2FA-489B-4F50-87E3-C8E166AE5946

P304

Q36931971-C67B9FF7-A92B-4BE9-AB46-07331396F96B

P31

Q36931971-7E4D8720-7BB4-461C-B80A-3002EF93CA1E

P356

Q36931971-787F436B-79A7-47DC-92A5-9059CD26757B

P433

Q36931971-6CCB5545-DBA5-4032-B47F-D78BA72D83F4

P478

Q36931971-8761941B-680F-44AA-A350-B48DB244DA00

P50

Q36931971-94E65F13-B4B9-4A75-8083-6FD00393EB3A

P577

Q36931971-FB8B5EDC-4853-4A17-9529-D258C698407E

P5875

Q36931971-11AC3F8D-712B-4F55-8854-4AF92D64D4E4

P698

Q36931971-4F7D8200-8A43-440C-905A-85EC44456880

P921

Q36931971-974791E6-C450-4C3B-99F3-F0CF81FE0AF8

P932

Q36931971-C3031A69-0528-4AFA-8F2C-13403E79BF54

P356

J.NBD.2008.01.015

P1433

Neurobiology of Disease

P1476

Sertraline slows disease progr ...... model of Huntington's disease.

@en

P2093

Bruce Ladenheim

http://www.w3.org/2001/XMLSchema#string

Eric Ford

http://www.w3.org/2001/XMLSchema#string

Erik Tryggestad

http://www.w3.org/2001/XMLSchema#string

Jean Lud Cadet

http://www.w3.org/2001/XMLSchema#string

John Wong

http://www.w3.org/2001/XMLSchema#string

Ming Zhao

http://www.w3.org/2001/XMLSchema#string

Naoki Masuda

http://www.w3.org/2001/XMLSchema#string

Qi Peng

http://www.w3.org/2001/XMLSchema#string

Wenzhen Duan

http://www.w3.org/2001/XMLSchema#string

P2860

Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series

Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

Huntingtin aggregation and toxicity in Huntington's disease

Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey

Protein aggregation and neurodegenerative disease

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

P304

312-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NBD.2008.01.015

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Christopher A Ross

P577

2008-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5449929

http://www.w3.org/2001/XMLSchema#string

P698

18403212

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3683653

http://www.w3.org/2001/XMLSchema#string